메뉴 건너뛰기




Volumn 9, Issue 1, 2011, Pages 57-63

Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010

Author keywords

Characteristics; Epidemiology; Incidence; Myelodysplastic syndromes; Risk factors

Indexed keywords

AGRICULTURAL CHEMICAL; ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; PESTICIDE;

EID: 78951473511     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0006     Document Type: Review
Times cited : (77)

References (50)
  • 2
    • 0015827903 scopus 로고
    • Preleukemia. The hematologic syndrome preceding acute leukemia
    • Saarni MI, Linman JW. Preleukemia. The hematologic syndrome preceding acute leukemia. Am J Med 1973;55:38-48.
    • (1973) Am J Med , vol.55 , pp. 38-48
    • Saarni, M.I.1    Linman, J.W.2
  • 3
    • 0037093195 scopus 로고    scopus 로고
    • Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
    • Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
    • (2002) J Clin Oncol , vol.20 , pp. 2429-2440
    • Silverman, L.R.1    Demakos, E.P.2    Peterson, B.L.3
  • 4
    • 33646071894 scopus 로고    scopus 로고
    • Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
    • Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-1803.
    • (2006) Cancer , vol.106 , pp. 1794-1803
    • Kantarjian, H.1    Issa, J.P.2    Rosenfeld, C.S.3
  • 5
    • 33749438404 scopus 로고    scopus 로고
    • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
    • List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-1465.
    • (2006) N Engl J Med , vol.355 , pp. 1456-1465
    • List, A.1    Dewald, G.2    Bennett, J.3
  • 6
    • 34247172535 scopus 로고    scopus 로고
    • Myelodysplastic syndromes: Incidence and survival in the United States
    • DOI 10.1002/cncr.22570
    • Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109:1536-1542. (Pubitemid 46595689)
    • (2007) Cancer , vol.109 , Issue.8 , pp. 1536-1542
    • Ma, X.1    Does, M.2    Raza, A.3    Mayne, S.T.4
  • 7
    • 47249150213 scopus 로고    scopus 로고
    • Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
    • Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
    • (2008) Blood , vol.112 , pp. 45-52
    • Rollison, D.E.1    Howlader, N.2    Smith, M.T.3
  • 8
    • 77956397358 scopus 로고    scopus 로고
    • Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries
    • Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010;28:2847-2852.
    • (2010) J Clin Oncol , vol.28 , pp. 2847-2852
    • Goldberg, S.L.1    Chen, E.2    Corral, M.3
  • 9
    • 0026688084 scopus 로고
    • Age-related incidence and other epidemiological aspects of myelodysplastic syndromes
    • Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992;82:358-367.
    • (1992) Br J Haematol , vol.82 , pp. 358-367
    • Aul, C.1    Gattermann, N.2    Schneider, W.3
  • 11
    • 0031398164 scopus 로고    scopus 로고
    • Age and sex distributions of hematological malignancies in the U.K
    • McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 1997;15:173-189.
    • (1997) Hematol Oncol , vol.15 , pp. 173-189
    • McNally, R.J.1    Rowland, D.2    Roman, E.3    Cartwright, R.A.4
  • 12
    • 0028955323 scopus 로고
    • Incidence of myelodysplastic syndromes in a Swedish population
    • Radlund A, Thiede T, Hansen S, et al. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 1995;54:153-156.
    • (1995) Eur J Haematol , vol.54 , pp. 153-156
    • Radlund, A.1    Thiede, T.2    Hansen, S.3
  • 13
    • 78649937642 scopus 로고    scopus 로고
    • Incidence and prevalence of patients with myelodysplastic syndromes (MDS) in Dusseldorf 1996-2005
    • abstract Abstract 1774
    • Neukirchen J, Schoonen WM, Aul C, et al. Incidence and prevalence of patients with myelodysplastic syndromes (MDS) in Dusseldorf 1996-2005 [abstract]. Blood 2009;114:Abstract 1774.
    • (2009) Blood , vol.114
    • Neukirchen, J.1    Schoonen, W.M.2    Aul, C.3
  • 14
    • 4944261763 scopus 로고    scopus 로고
    • Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia
    • Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004;104:2263-2268.
    • (2004) Blood , vol.104 , pp. 2263-2268
    • Guralnik, J.M.1    Eisenstaedt, R.S.2    Ferrucci, L.3
  • 15
    • 62849104641 scopus 로고    scopus 로고
    • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
    • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
    • (2009) Lancet Oncol , vol.10 , pp. 223-232
    • Fenaux, P.1    Mufti, G.J.2    Hellstrom-Lindberg, E.3
  • 16
    • 55749114037 scopus 로고    scopus 로고
    • Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys
    • Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008;100:1542-1551.
    • (2008) J Natl Cancer Inst , vol.100 , pp. 1542-1551
    • Sekeres, M.A.1    Schoonen, W.M.2    Kantarjian, H.3
  • 17
    • 0023264243 scopus 로고
    • Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy
    • Pedersen-Bjergaard J, Specht L, Larsen SO, et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987;2:83-88.
    • (1987) Lancet , vol.2 , pp. 83-88
    • Pedersen-Bjergaard, J.1    Specht, L.2    Larsen, S.O.3
  • 18
    • 0037837665 scopus 로고    scopus 로고
    • Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience
    • DOI 10.1200/JCO.2003.03.114
    • Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21:1195-1204. (Pubitemid 46894010)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.7 , pp. 1195-1204
    • Smith, R.E.1    Bryant, J.2    DeCillis, A.3    Anderson, S.4
  • 19
    • 0028326283 scopus 로고
    • The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation
    • Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994;83:2780-2786.
    • (1994) Blood , vol.83 , pp. 2780-2786
    • Pedersen-Bjergaard, J.1    Rowley, J.D.2
  • 20
    • 0036197483 scopus 로고    scopus 로고
    • International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: Overview report
    • Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer 2002;33:331-345.
    • (2002) Genes Chromosomes Cancer , vol.33 , pp. 331-345
    • Rowley, J.D.1    Olney, H.J.2
  • 21
    • 0028956093 scopus 로고
    • Therapy-related myelodysplasia and acute leukemia
    • Pedersen-Bjergaard J. Therapy-related myelodysplasia and acute leukemia. Leuk Lymphoma 1995;15(Suppl 1):11-12.
    • (1995) Leuk Lymphoma , vol.15 , Issue.SUPPL. 1 , pp. 11-12
    • Pedersen-Bjergaard, J.1
  • 22
    • 0028871987 scopus 로고
    • Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia
    • Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995;86:3542-3552.
    • (1995) Blood , vol.86 , pp. 3542-3552
    • Pedersen-Bjergaard, J.1    Pedersen, M.2    Roulston, D.3    Philip, P.4
  • 24
    • 33747061875 scopus 로고    scopus 로고
    • Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia
    • Kalaycio M, Rybicki L, Pohlman B, et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 2006;24:3604-3610.
    • (2006) J Clin Oncol , vol.24 , pp. 3604-3610
    • Kalaycio, M.1    Rybicki, L.2    Pohlman, B.3
  • 25
    • 58249093949 scopus 로고    scopus 로고
    • Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs
    • Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009;27:250-255.
    • (2009) J Clin Oncol , vol.27 , pp. 250-255
    • Leleu, X.1    Soumerai, J.2    Roccaro, A.3
  • 26
    • 0142058040 scopus 로고    scopus 로고
    • Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group
    • Josting A, Wiedenmann S, Franklin J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3440-3446.
    • (2003) J Clin Oncol , vol.21 , pp. 3440-3446
    • Josting, A.1    Wiedenmann, S.2    Franklin, J.3
  • 27
    • 0038305924 scopus 로고    scopus 로고
    • Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series
    • Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52.
    • (2003) Blood , vol.102 , pp. 43-52
    • Smith, S.M.1    Le Beau, M.M.2    Huo, D.3
  • 28
    • 33845354279 scopus 로고    scopus 로고
    • Second malignancy risk associated with treatment of Hodgkin's lymphoma: Meta-analysis of the randomised trials
    • Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006;17:1749-1760.
    • (2006) Ann Oncol , vol.17 , pp. 1749-1760
    • Franklin, J.1    Pluetschow, A.2    Paus, M.3
  • 30
    • 33846032244 scopus 로고    scopus 로고
    • Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group
    • Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group. Blood 2007;109:46-51.
    • (2007) Blood , vol.109 , pp. 46-51
    • Bhatia, S.1    Krailo, M.D.2    Chen, Z.3
  • 31
    • 0037100301 scopus 로고    scopus 로고
    • Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: Comparison with primary presentation
    • Barnard DR, Lange B, Alonzo TA, et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood 2002;100:427-434.
    • (2002) Blood , vol.100 , pp. 427-434
    • Barnard, D.R.1    Lange, B.2    Alonzo, T.A.3
  • 32
    • 16844382731 scopus 로고    scopus 로고
    • Insights into leukemogenesis from therapy-related leukemia
    • Pedersen-Bjergaard J. Insights into leukemogenesis from therapy-related leukemia. N Engl J Med 2005;352:1591-1594.
    • (2005) N Engl J Med , vol.352 , pp. 1591-1594
    • Pedersen-Bjergaard, J.1
  • 33
    • 20444423607 scopus 로고    scopus 로고
    • Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
    • McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005;105:4573-4575.
    • (2005) Blood , vol.105 , pp. 4573-4575
    • McLaughlin, P.1    Estey, E.2    Glassman, A.3
  • 34
    • 0023113215 scopus 로고
    • Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease
    • Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987;316:710-714.
    • (1987) N Engl J Med , vol.316 , pp. 710-714
    • Blayney, D.W.1    Longo, D.L.2    Young, R.C.3
  • 35
    • 0035047956 scopus 로고    scopus 로고
    • Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV)
    • Wheeler C, Khurshid A, Ibrahim J, et al. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma 2001;40:499-509.
    • (2001) Leuk Lymphoma , vol.40 , pp. 499-509
    • Wheeler, C.1    Khurshid, A.2    Ibrahim, J.3
  • 36
    • 33644875971 scopus 로고    scopus 로고
    • Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk
    • CD003187
    • Franklin JG, Paus MD, Pluetschow A, Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev 2005:CD003187.
    • (2005) Cochrane Database Syst Rev
    • Franklin, J.G.1    Paus, M.D.2    Pluetschow, A.3    Specht, L.4
  • 37
    • 20144389274 scopus 로고    scopus 로고
    • Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study
    • Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-2670.
    • (2005) Blood , vol.105 , pp. 2664-2670
    • Finazzi, G.1    Caruso, V.2    Marchioli, R.3
  • 38
    • 77950548083 scopus 로고    scopus 로고
    • Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS)
    • Du Y, Fryzek J, Sekeres MA, Taioli E. Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk Res 2009;9:9.
    • (2009) Leuk Res , vol.9 , pp. 9
    • Du, Y.1    Fryzek, J.2    Sekeres, M.A.3    Taioli, E.4
  • 39
    • 0026527211 scopus 로고
    • Exposure to organic solvents and risk of haematological malignancies
    • Brandt L. Exposure to organic solvents and risk of haematological malignancies. Leuk Res 1992;16:67-70.
    • (1992) Leuk Res , vol.16 , pp. 67-70
    • Brandt, L.1
  • 40
    • 0031906395 scopus 로고    scopus 로고
    • Pathogenesis, etiology and epidemiology of myelodysplastic syndromes
    • Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998;83:71-86.
    • (1998) Haematologica , vol.83 , pp. 71-86
    • Aul, C.1    Bowen, D.T.2    Yoshida, Y.3
  • 41
    • 27644448871 scopus 로고    scopus 로고
    • Risk factors of myelodysplastic syndromes: A case-control study
    • Strom SS, Gu Y, Gruschkus SK, et al. Risk factors of myelodysplastic syndromes: a case-control study. Leukemia 2005;19:1912-1918.
    • (2005) Leukemia , vol.19 , pp. 1912-1918
    • Strom, S.S.1    Gu, Y.2    Gruschkus, S.K.3
  • 42
    • 0035048651 scopus 로고    scopus 로고
    • Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France
    • Nisse C, Haguenoer JM, Grandbastien B, et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. Br J Haematol 2001;112:927-935.
    • (2001) Br J Haematol , vol.112 , pp. 927-935
    • Nisse, C.1    Haguenoer, J.M.2    Grandbastien, B.3
  • 43
    • 0025151821 scopus 로고
    • Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: Correlation with chromosome patterns and data on patients without hematological disease
    • Goldberg H, Lusk E, Moore J, et al. Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: correlation with chromosome patterns and data on patients without hematological disease. Cancer Res 1990;50:6876-6881.
    • (1990) Cancer Res , vol.50 , pp. 6876-6881
    • Goldberg, H.1    Lusk, E.2    Moore, J.3
  • 44
    • 0028968897 scopus 로고
    • Occupational and environmental exposures and myelodysplasia: A case-control study
    • West RR, Stafford DA, Farrow A, Jacobs A. Occupational and environmental exposures and myelodysplasia: a case-control study. Leuk Res 1995;19:127-139.
    • (1995) Leuk Res , vol.19 , pp. 127-139
    • West, R.R.1    Stafford, D.A.2    Farrow, A.3    Jacobs, A.4
  • 45
    • 0030897009 scopus 로고    scopus 로고
    • International scoring system for evaluating prognosis in myelodysplastic syndromes
    • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
    • (1997) Blood , vol.89 , pp. 2079-2088
    • Greenberg, P.1    Cox, C.2    LeBeau, M.M.3
  • 46
    • 34548219420 scopus 로고    scopus 로고
    • Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
    • Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
    • (2007) J Clin Oncol , vol.25 , pp. 3503-3510
    • Malcovati, L.1    Germing, U.2    Kuendgen, A.3
  • 47
    • 53149113768 scopus 로고    scopus 로고
    • Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
    • Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361.
    • (2008) Cancer , vol.113 , pp. 1351-1361
    • Kantarjian, H.1    O'Brien, S.2    Ravandi, F.3
  • 48
    • 78649962804 scopus 로고    scopus 로고
    • Perceptions of disease state, treatment expectations, and prognosis among patients with myelodysplastic syndromes
    • abstract Abstract 1771
    • Sekeres MA, Maciejewski JP, List AF, et al. Perceptions of disease state, treatment expectations, and prognosis among patients with myelodysplastic syndromes [abstract]. Blood 2009;114:Abstract 1771.
    • (2009) Blood , vol.114
    • Sekeres, M.A.1    Maciejewski, J.P.2    List, A.F.3
  • 50
    • 77949480045 scopus 로고    scopus 로고
    • Treatment of MDS: Something old, something new, something borrowed
    • Sekeres MA. Treatment of MDS: something old, something new, something borrowed. Hematology Am Soc Hematol Educ Program 2009:656-663.
    • (2009) Hematology Am Soc Hematol Educ Program , pp. 656-663
    • Sekeres, M.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.